RxDoctor Payments Data

Joseph Meserve, MD

Gastroenterology · Columbia, SCNPI 1083001473

Payments from drug & device makers

What this record shows

This record is dominated by grants: $80,000 of the $86,306 with a category attached, or 92.7%. Pfizer accounts for 96.3% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2022 at $65,814 and has fallen 99.9% since, to $92 in 2025. Among gastroenterology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$86,306in general payments, 2019–2025

Across 41 payments — averaging $2105.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$83K
  • Janssen Research & Development, LLC$1K
  • AbbVie$829
  • Cook Medical LLC$392
  • Boston Scientific$192
  • Johnson & Johnson$190
  • plus $491 from 6 others
$131in research payments, 2019–2025

Across 3 payments — averaging $43.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$131

What the payments were for

  • Consulting fees$3,0003%
  • Speaking & faculty fees$3400%
  • Grants$80,00093%
  • Travel & lodging$1,0011%
  • Food & beverage$1,6832%
  • Education$2820%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$86,306 in reported general payments places this provider in the 95th percentile of 259 gastroenterology providers in South Carolina.

See all gastroenterology providers in South Carolina

Medicare billing

Part B allowed, 2024
$37,759
Medicare patients
177
Services billed
278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide14$7,463
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl107$1,757
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl41$650
Pantoprazole Sodium52$608
Sucralfate15$440
Omeprazole36$415
Dicyclomine Hcl23$308
Ondansetron Hcl17$236
Prednisone17$163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$829$7,46314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 259 gastroenterology providers in South Carolina.

Other gastroenterology in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →